Subscribe
dacian-g-shutterstock-com
Dacian G / Shutterstock.com
3 September 2015Americas

Bass suffers another IPR setback

Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

More on this story

Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.

More features

Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal